



**Company Contact:**  
**Richard Gabriel**  
**CEO and President**  
**941 366-3400**  
**-or-**  
**Ron Stabiner**  
**The Wall Street Group, Inc.**  
**212-888-4848**

**FOR IMMEDIATE RELEASE**

**SOUTH LOUISIANA SERIAL KILLER WORKSHOP TO BE PRESENTED AT THE  
AMERICAN ACADEMY OF FORENSICS SCIENCE (AAFS) ANNUAL MEETING  
ON FEBRUARY 20, 2006 in SEATTLE, WASHINGTON**

**SARASOTA, Fla., Feb 16, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG)** today announced that Dr. Matthew Thomas, Senior Scientist, is a scheduled speaker at the South Louisiana Serial Killer Workshop at the AAFS Annual Meeting on February 20, 2006 in Seattle, Washington. Dr. Thomas will explain DNAPrint Genomics' role in focusing investigation efforts towards the correct suspect, Derrick Todd Lee, in the South Louisiana Serial Killer case. Dr. Thomas's presentation will explain the science behind the DNAWitness™ product and demonstrate the process that resulted in test results reflecting Derrick Todd Lee's 85% Sub-Saharan African ancestry. This information was instrumental in focusing investigation efforts on appropriate suspects. The refocused investigation resulted in an arrest less than two months after DNAPrint Genomics provided the information and the suspect was ultimately convicted.

The American Academy of Forensic Sciences is one of the world's largest and most renowned organizations of forensic scientists, with nearly 6,000 members in 57 countries. The annual meeting involves presentation of scientific papers and workshops designed to keep forensic scientists on the cutting edge of solving crime. One such workshop at this year's meeting involves a very complex, multifaceted investigation, which culminated in the apprehension and conviction of a serial killer. The experts involved in the case, including an investigator, several scientists, the profiler and legal experts, will come together to share their expertise and learning experiences, in the hopes of educating attendees so they can solve similar crimes more efficiently in their home jurisdictions.

In 2002 and 2003, murders of six victims were linked to a single assailant in Southern Louisiana. Multiple agencies were involved in the investigation and eventual prosecution of the cases, culminating in the death penalty sentence of Derrick Todd Lee in 2004. The hunt for the serial killer generated considerable media coverage, and resulted in wide sweeping effects to policy, legislation and funding. A variety of approaches were taken in the forensic investigation and prosecution of the crimes, including a blending of new technologies and trusted older techniques. The investigative use of databases generated unique leads when applied to the field of physical matching and comparison. A variety of DNA analytical methods, techniques, and applications were employed to link crimes together, eliminate suspects, implicate Lee, and bring novel investigative information to the serial killer task force, including ancestry determination which demonstrated that he was 85% African.

"The successful outcome of the Louisiana Serial Killer case in 2003 was a milestone for our DNAWitness forensic technology and brought nationwide attention to DNAPrint's capabilities in helping to solve complex crimes," stated President and Chief Executive Officer Richard Gabriel.

(MORE)

“Since that time, DNAWitness or Retinome™ technologies are currently being utilized in more than 100 cases worldwide. Retinome™ provides an accurate inference of iris (eye) color from the measurement of proprietary single nucleotide polymorphisms (SNPs) distributed throughout the human genome and is a further advancement of DNAWitness technology. We are proud of our role in this investigation and we believe that there are many cases that would benefit from the application of our forensic technologies.”

The forensic community will benefit by learning the keys to success, and avoiding the pitfalls, in large, multidiscipline, multiple murder investigations. Techniques learned will be immediately employable by forensic scientists, investigators and administrators in their own jurisdictions and casework. The forensic community and society as a whole will benefit through protection of individuals’ rights by rapid exoneration of innocent suspects, the increased public safety resulting from early apprehension of serial predators, and the reduced-cost benefit of an effective investigation using the latest technology.

#### **About DNAPrint Genomics, Inc.**

DNAPrint Genomics, Inc. ([www.dnaprint.com](http://www.dnaprint.com)) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (end stage renal disease). Pre-clinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to better design actual trials and are targeted to patients with a genetic profile indicating their propensity to have the best clinical response. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to [www.dnaprint.com](http://www.dnaprint.com) for information on law enforcement and consumer applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM) and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

#### **Forward-Looking Statements**

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation, to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.

###